• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Melis, M H M
    Simpson, Kathryn L
    Dovedi, Simon J
    Welman, Arkadiusz
    MacFarlane, M
    Dive, Caroline
    Honeychurch, Jamie
    Illidge, Timothy M
    Affiliation
    Targeted Therapy, Institute of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
    Issue Date
    2013-05
    
    Metadata
    Show full item record
    Abstract
    Effective anticancer treatments often result in the induction of large amounts of tumour cell death. In vivo, such dying tumour cells are a potential source of antigens for T-cell stimulation. Although apoptosis is generally considered nonimmunogenic, recent evidence suggests that some anticancer therapies that induce apoptosis can elicit antitumour immune responses. Here, a doxycycline-inducible, constitutively active caspase-3 ('death switch') was constructed in a murine tumour model to explore the impact of the host immune response to rapid, synchronous and substantial tumour cell apoptosis. In vitro, up to 80% of tumour cells underwent apoptotic cell death within 24 h and death was accompanied by the release of potential 'danger signal' molecules HMGB1 and HSP90. In vivo, death switch induction provoked rapid, pronounced tumour regression in immune-competent and immune-deficient mice, but sustained tumour eradication was observed only in immune-competent mice. Moreover, the majority of mice that were tumour free after death switch induction were protected from further tumour rechallenge. In addition, long-term remission after induction of the death switch was completely abrogated following depletion of CD8 T cells. These data suggest that sustained tumour eradication after substantial tumour apoptosis requires an antitumour host immune response that prevents tumour relapse. In many patients, cancer therapies produce encouraging initial responses that are only short lived. These results provide new insights that may have important implications for further development of strategies that result in long-term tumour clearance after initially effective anticancer treatment.
    Citation
    Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response. 2013, 20 (5):765-73 Cell Death Differ
    Journal
    Cell Death and Differentiation
    URI
    http://hdl.handle.net/10541/294006
    DOI
    10.1038/cdd.2013.8
    PubMed ID
    23412345
    Type
    Article
    Language
    en
    ISSN
    1476-5403
    ae974a485f413a2113503eed53cd6c53
    10.1038/cdd.2013.8
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers.
    • Authors: Simpson KL, Cawthorne C, Zhou C, Hodgkinson CL, Walker MJ, Trapani F, Kadirvel M, Brown G, Dawson MJ, MacFarlane M, Williams KJ, Whetton AD, Dive C
    • Issue date: 2013 May 2
    • Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.
    • Authors: Werthmöller N, Frey B, Wunderlich R, Fietkau R, Gaipl US
    • Issue date: 2015 May 14
    • Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    • Authors: Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R
    • Issue date: 2003 Dec 1
    • N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
    • Authors: Ishii-Osai Y, Yamashita T, Tamura Y, Sato N, Ito A, Honda H, Wakamatsu K, Ito S, Nakayama E, Okura M, Jimbow K
    • Issue date: 2012 Jul
    • A blast without power - cell death induced by the tuberculosis-necrotizing toxin fails to elicit adequate immune responses.
    • Authors: Maueröder C, Chaurio RA, Dumych T, Podolska M, Lootsik MD, Culemann S, Friedrich RP, Bilyy R, Alexiou C, Schett G, Berens C, Herrmann M, Munoz LE
    • Issue date: 2016 Jun
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.